Edited by: Hans-Uwe Simon
Eosinophilic granulomatosis with polyangiitis (Churg–Strauss): state of the art
Article first published online: 18 JAN 2013
© 2013 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd
Volume 68, Issue 3, pages 261–273, March 2013
How to Cite
Eosinophilic granulomatosis with polyangiitis (Churg–Strauss): state of the art. Allergy 2013; 68: 261–273., , .
- Issue published online: 8 FEB 2013
- Article first published online: 18 JAN 2013
- Manuscript Accepted: 30 OCT 2012
- clinical immunology;
- immunologic tests;
Eosinophilic granulomatosis with polyangiitis (Churg–Strauss, EGPA) is a systemic small-vessel vasculitis associated with asthma and eosinophilia. Histology of EGPA shows tissue eosinophilia, necrotizing vasculitis, and eosinophil-rich granulomatous inflammation. EGPA commonly presents with upper airway tract and lung involvement, peripheral neuropathy, cardiac and skin lesions. Antineutrophil cytoplasmic antibodies (ANCA) are positive in ∼40% of the cases and more often in patients with clinical manifestations due to small-vessel vasculitis. The pathogenesis of EGPA is multifactorial: the disease can be triggered by exposure to allergens or drugs, but a genetic background has also been recognized, particularly an association with HLA-DRB4. Th2 responses are prominent, with up-regulation of IL-4, IL-13, and IL-5; however, Th1 and Th17 responses are not negligible. Eosinophils are activated, have a prolonged lifespan and probably cause tissue damage by releasing their granule proteins; their tissue recruitment can be regulated by chemokines such as eotaxin-3 and CCL17. Humoral immunity is also dysregulated, as demonstrated by prominent IgG4 and IgE responses. EGPA promptly responds to glucocorticoid therapy, although combinations of glucocorticoids and immunosuppressants (e.g., cyclophosphamide, azathioprine) are eventually required in most cases. Newer therapeutic options include the anti-IL5 antibody mepolizumab, whose efficacy has been described in small clinical trials, and the B-cell-depleting agent rituximab, reported in several case series.